Literature DB >> 16766403

Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient.

Holger Baatz1, Alireza Mirshahi, Joachim Puchta, Hermann Gümbel, Lars-Olof Hattenbach.   

Abstract

PURPOSE: To report a case of toxoplasma retinochoroiditis reactivation in an immunocompetent patient under atovaquone therapy.
METHODS: Case report.
RESULTS: A healthy woman with a history of bilateral toxoplasma retinochoroiditis since childhood presented with a reactivation of toxoplasma retinochoroiditis. Because earlier treatment regimens had either produced intolerable side effects and/or were deemed ineffective for the prevention of reactivation, the patient was started on atovaquone suspension (750 mg three times a day). After initial regression of the lesion and still under atovaquone therapy, the patient presented again five weeks later with worsened best-corrected visual acuity. Examination showed that the lesion had expanded again and more cells were present in the vitreous.
CONCLUSIONS: To our knowledge, this is the first report of a reactivation of toxoplasma retinochoroiditis in an immunocompetent patient under atovaquone therapy, possibly indicating tachyzoite resistance to atovaquone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766403     DOI: 10.1080/09273940600659740

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  21 in total

1.  Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.

Authors:  Danièle Maubon; Alexandre Bougdour; Yung-Sing Wong; Marie-Pierre Brenier-Pinchart; Aurélie Curt; Mohamed-Ali Hakimi; Hervé Pelloux
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

Review 2.  Current approach in the diagnosis and management of posterior uveitis.

Authors:  S Sudharshan; Sudha K Ganesh; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

3.  CRISPR/Cas9 and glycomics tools for Toxoplasma glycobiology.

Authors:  Elisabet Gas-Pascual; Hiroshi Travis Ichikawa; Mohammed Osman Sheikh; Mariam Isabella Serji; Bowen Deng; Msano Mandalasi; Giulia Bandini; John Samuelson; Lance Wells; Christopher M West
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

4.  Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy.

Authors:  Sarmad N Mageed; Fraser Cunningham; Alvin Wei Hung; Hernani Leonardo Silvestre; Shijun Wen; Tom L Blundell; Chris Abell; Glenn A McConkey
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

5.  Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica.

Authors:  Fabrice F Boyom; Patrick V T Fokou; Lauve R Y Tchokouaha; Thomas Spangenberg; Alvine N Mfopa; Ruffin M T Kouipou; Cedric J Mbouna; Valerie F Donkeng Donfack; Paul H A Zollo
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

6.  Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii.

Authors:  Alex Rosenberg; Madeline R Luth; Elizabeth A Winzeler; Michael Behnke; L David Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-05       Impact factor: 11.205

7.  The role of DNA microarrays in Toxoplasma gondii research, the causative agent of ocular toxoplasmosis.

Authors:  Kevin M Brown; Ira J Blader
Journal:  J Ocul Biol Dis Infor       Date:  2009-12-12

Review 8.  Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence.

Authors:  Ira J Blader; Jeroen P Saeij
Journal:  APMIS       Date:  2009-05       Impact factor: 3.205

9.  In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.

Authors:  Pascale Meneceur; Marie-Anne Bouldouyre; Dominique Aubert; Isabelle Villena; Jean Menotti; Virginie Sauvage; Jean-François Garin; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

10.  Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.

Authors:  Ildiko R Dunay; Wing Chi Chan; Richard K Haynes; L David Sibley
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.